Increased expression of Siglec-9 in chronic obstructive pulmonary disease

Zhilin Zeng1,2, Miao Li1, Meijia Wang1, Xiaomei Wu1, Qinghai Li1, Qin Ning2, Jianping Zhao1, Yongjian Xu1 & Jungang Xie1

Chronic obstructive pulmonary disease (COPD) is a common inflammatory lung disease. Sialic acid-binding immunoglobulin-type lectins 9 (Siglec-9) is predominantly expressed on innate immune cells and has been shown to exert regulatory effect on immune cells through glycan recognition. Soluble Siglec-9 (sSiglec-9), the extracellular region of Siglec-9, might fulfill its function partly by competitive inhibiting siglec-9 binding to its ligands; however, the role of Siglec-9 and sSiglec-9 in the pathogenesis COPD remain largely unknown. In this study, we showed that Siglec-9 expression in alveolar and peripheral blood neutrophil were increased in COPD patients by immunofluorescence and flow cytometry, respectively. Plasma levels of sSiglec-9 were elevated in COPD patients by ELISA. In vitro, Siglec-9 expression and/or sSiglec-9 levels were up-regulated by cigarette smoke extract (CSE), lipopolysaccharide (LPS), some cytokines, and dexamethasone (DEX). Recombinant sSiglec-9 increased oxidative burst in neutrophil and enhanced neutrophil chemotaxis toward IL-8 independent on CXCR1 and CXCR2 expression, but it did not affect neutrophil apoptosis or secretions of inflammatory cytokines. In conclusion, Siglec-9 was complementarily increased to induce a negative feedback loop to limit neutrophil activation in COPD, sSiglec-9 enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibiting ligands binding to Siglec-9.
ment with LPS in a concentration-dependent manner (Fig. 3b,d).

had no effect on expression of Siglec-9. Siglec-9 expression and sSiglec-9 secretion were up-regulated after treat-

supernatant (307.3 ± 29.07 versus 241.3 ± 25.98, \( p = 0.0051 \)) by flow cytometry. The level of plasma sSiglec-9 in COPD patients was higher than controls (152.20 ± 11.03 versus 116.00 ± 9.723 pg/ml, \( p = 0.0449 \)) (Fig. 1b).

Increased Siglec-9 expression in alveolar neutrophil in COPD patients. Figure 1a showed that neutrophil Siglec-9 expression was significantly increased in COPD patients compared with controls (MFI 27533 ± 2020 versus 17468 ± 2598, \( p = 0.0051 \)) by flow cytometry. The level of plasma sSiglec-9 in COPD patients was higher than controls (152.20 ± 11.03 versus 116.00 ± 9.723 pg/ml, \( p = 0.0449 \)) (Fig. 1b).

Increased expression of neutrophil Siglec-9 and levels of plasma sSiglec-9 in COPD patients. Figure 1a showed that neutrophil Siglec-9 expression was significantly increased in COPD patients compared with controls (MFI 27533 ± 2020 versus 17468 ± 2598, \( p = 0.0051 \)) by flow cytometry. The level of plasma sSiglec-9 in COPD patients was higher than controls (152.20 ± 11.03 versus 116.00 ± 9.723 pg/ml, \( p = 0.0449 \)) (Fig. 1b).

Results

Subject characteristics. Clinical characteristics of two group subjects providing for peripheral blood or BALF were shown in Supplementary Tables S1 and S2, respectively. In both of them, the average age and smoking history of COPD patients were similar to those of controls. Compared with COPD patients, controls exhibited significantly higher levels of FEV1 (\( p < 0.05 \)), FEV1% of predicted (\( p < 0.01 \)), and FEV1/FVC% (\( p < 0.01 \)).

Increased expression of neutrophil Siglec-9 and levels of plasma sSiglec-9 in COPD patients. Figure 1a showed that neutrophil Siglec-9 expression was significantly increased in COPD patients compared with controls (MFI 27533 ± 2020 versus 17468 ± 2598, \( p = 0.0051 \)) by flow cytometry. The level of plasma sSiglec-9 in COPD patients was higher than controls (152.20 ± 11.03 versus 116.00 ± 9.723 pg/ml, \( p = 0.0449 \)) (Fig. 1b).

Increased Siglec-9 expression in alveolar neutrophil in COPD patients. Siglec-9 expression in lung tissue was assessed by immunohistochemistry. Neutrophil and other inflammatory cells showed positive Siglec-9 staining in human alveolar spaces (Fig. 2a).

In order to determine the expression of Siglec-9 in alveolar macrophage and neutrophil, we performed dual immunofluorescence staining for Siglec-9 and CD68 (marker of macrophage) to detect macrophage and carried out H&E staining in corresponding slides to localized neutrophil. As shown in Fig. 2b and c, both alveolar macrophage and neutrophil expressed Siglec-9. Siglec-9 expression in alveolar neutrophil was markedly increased in COPD patients relative to controls. But no difference was detected in Siglec-9 expression in alveolar macrophage between two groups (Fig. 2b). To further confirm that results, the expression of Siglec-9 mRNA in alveolar macrophage was assessed by real-time PCR. Consistent with the immunofluorescence results, Siglec-9 mRNA expression was similar in COPD patients and controls (Fig. 2d).

Neutrophil Siglec-9 expression and sSiglec-9 levels in culture supernatant were up-regulated by CSE and LPS. To assess the potential effect of CSE and LPS on neutrophil Siglec-9 expression and sSiglec-9 levels in culture supernatant, neutrophil was stimulated with various concentrations of CSE and LPS for 12h. Only 0.5% CSE induced neutrophil Siglec-9 expression relative to control cells (MFI 4461 ± 425 versus 3575 ± 298.7, \( p = 0.0042 \)) (Fig. 3a). Similarly, just 0.5% CSE significantly increased sSiglec-9 levels in culture supernatant (307.3 ± 29.07 versus 241.3 ± 20.42 pg/ml, \( p = 0.0010 \)) (Fig. 3c), while other concentrations of CSE had no effect on expression of Siglec-9. Siglec-9 expression and sSiglec-9 secretion were up-regulated after treatment with LPS in a concentration-dependent manner (Fig. 3b,d).
Effect of cytokines on Siglec-9 and sSiglec-9 expression. CSE and LPS can induce neutrophil to secret TNF-α, IL-6, and IL-8 which contribute to the development of COPD. Siglec-9 expression was remarkably up-regulated after incubation with 50 ng/ml (MFI 7519 ± 829.8 versus 6529 ± 594.7, \( p = 0.018 \)), 200 ng/ml TNF-α (MFI 8686 ± 1058 versus 6529 ± 594.7, \( p = 0.0185 \)), and IL-8 (MFI 7607 ± 502.7 versus 6752 ± 358.9, \( p = 0.0124 \)) compared to controls (Fig. 4a,b), while different concentrations of IL-6 had no effect on Siglec-9 expression (Fig. 4b). TNF-α significantly induced a higher production of sSiglec-9 relative to control cells (Fig. 4c); similar results were obtained when cells were treated with IL-6 and IL-8 (Fig. 4d).

Dexamethasone augmented neutrophil Siglec-9 expression but not sSiglec-9 levels in culture supernatant. Corticosteroids are the most widely used anti-inflammatory therapy for the treatment of COPD. We found that 10^{-4} M DEX (MFI 8116 ± 705.4 versus 6594 ± 377.9, \( p = 0.0211 \)) but not 10^{-6} M DEX augmented Siglec-9 expression but DEX did not regulate sSiglec-9 production in culture supernatant (Fig. 5a,b).

Oxidative burst in neutrophil was increased by sSiglec-9 treatment. Basal levels of intracellular ROS in neutrophil were 178915 ± 29102 (MFI), significantly lower than ones treated by 100 ng/ml sSiglec-9 (MFI 210993 ± 35751, \( p = 0.0219 \)) and IL-8 (as positive control, MFI 215494 ± 35750, \( p = 0.0381 \)), indicating that both aSiglec-9 and IL-8 induced oxidative stress (Fig. 6a).

Soluble Siglec-9 enhanced neutrophil chemotaxis toward IL-8 independent of CXCR1 and CXCR2 expression. To characterize the role of sSiglec-9 in the migration of neutrophil, we examined the effect of sSiglec-9 on the random and directional (toward IL-8) neutrophil migration by using a transwell assay. As shown in Fig. 6b, neutrophil migration was significantly greater in the presence of IL-8 (\( p < 0.001 \)). The migratory response of neutrophils toward IL-8 was enhanced by 10 ng/ml sSiglec-9 (30002 ± 3609 versus 23357 ± 3102 cells, \( p = 0.0232 \)) and 100 ng/ml sSiglec-9 (26893 ± 3510 versus 23357 ± 3102 cells, \( p = 0.0239 \)) (Fig. 6b); however, there were no sSiglec-9-concentration-dependent changes in IL-8-induced neutrophil migration. Besides, there was no change in the ability of neutrophil to migrate that were only pretreated with sSiglec-9.

As CXCR1 and CXCR2 play a critical role in neutrophil migration, we evaluated whether their expression was changed under sSiglec-9 incubation for 2 h. Unfortunately, sSiglec-9 had no effect on their expression (Fig. 6c,d).

CSE-induced or LPS-reduced neutrophil apoptosis were not altered by sSiglec-9. Compared with controls (35.71 ± 6.591), the percentage of apoptotic cells was higher in 2.5% CSE-treated cells (64.87 ± 5.062, \( p = 0.0011 \)) but lower in LPS-treated cells (23.04 ± 6.454, \( p = 0.0035 \)) (Fig. 7a); however, there was no effect of sSiglec-9 on neutrophil apoptosis induced by 2.5% CSE or reduced by LPS (Fig. 7a).
Soluble Siglec-9 had no effect on neutrophil inflammatory cytokine secretion. Compared with relative controls, CSE and LPS induced neutrophil secretion of IL-6 (CSE: 27.69 ± 1.610 versus 19.06 ± 2.318 pg/ml; p = 0.0030; LPS: 92.64 ± 14.31 versus 19.06 ± 2.318 pg/ml, p = 0.0003) (Fig. 7b), IL-8 (CSE: 2103 ± 97.30 versus 1311 ± 100.7 pg/ml, p < 0.0001; LPS: 3505 ± 162.6 versus 1311 ± 100.7 pg/ml, p < 0.0001) (Fig. 7c) and TNF-α (CSE: 52.61 ± 8.370 versus 39.73 ± 5.170 pg/ml, P = 0.0060; LPS: 90.24 ± 11.52 versus 39.73 ± 5.170 pg/ml, p < 0.0001) (Fig. 7d); however, sSiglec-9 did not affect neutrophil inflammatory cytokines secretion induced by CSE or LPS.

Soluble Siglec-9 enhanced LPS-induced HBE IL-8 secretion. HBE secreted higher IL-8 and IL-6 levels than controls after stimulation with 10% CSE (IL-8: 863 ± 124.5 versus 518.9 ± 81.00 pg/ml, p < 0.05; IL-6: 557.8 ± 45.21 versus 359.5 ± 58.85 pg/ml, p < 0.05) and 20 ng/ml LPS (IL-8: 1351 ± 116.6 versus 518.9 ± 81.00 pg/ml, p < 0.001; IL-6: 757.5 ± 99.63 versus 359.5 ± 58.85 pg/ml, p < 0.001) for 24h (Fig. 8a,b). Only sSiglec-9 treatment had no effect on IL-8 secretion but pretreatment with 10 ng/ml (2153 ± 238.7 versus 1351 ± 116.6 pg/ml, p < 0.05) and 100 ng/ml (1812 ± 215.9 versus 1351 ± 116.6 pg/ml, p < 0.05) sSiglec-9 enhanced IL-8 secretion in the milieu of LPS but not CSE (Fig. 8a). Different concentrations of sSiglec-9 had no effect on CSE- and LPS-induced HBE IL-6 production (Fig. 8b).

Discussion
In this study, we showed that neutrophil Siglec-9 expression and sSiglec-9 levels in plasma were increased in COPD patients. In vitro, CSE and LPS-induced neutrophil Siglec-9 expression were likely through TNF-α and IL-8; sSiglec-9 was likewise elevated by CSE and LPS presumably via TNF-α, IL-6, and IL-8, whereas DEX only augmented neutrophil Siglec-9 expression but not sSiglec-9 levels in supernatant. As an additional functional verification, we found that sSiglec-9 increased oxidative burst in neutrophil and enhanced neutrophil chemotaxis.
toward IL-8. Taken together, Siglec-9 was complementarily increased to inhibit neutrophil activation in COPD patients and in cell model incubation with CSE and LPS. Instead, sSiglec-9 levels was higher in COPD patients than controls and subsequently enhanced neutrophil ROS and chemotaxis toward IL-8 probably via competitive inhibiting ligands binding to Siglec-9. Furthermore, DEX might exert an anti-inflammatory role through up-regulating Siglec-9 expression.

Neutrophil Siglec-9 expression was shown to be involved in septic shock and rheumatoid arthritis patients. We found that Siglec-9 expression of alveolar and peripheral blood neutrophil were significantly increased in COPD patients. As Siglec-9 played a role in inhibiting immune response, so compensated elevation of Siglec-9 expression might exert a negative feedback loop to limit neutrophil responses. Besides, plasma sSiglec-9 levels were significantly higher in COPD patients than controls.

Soluble Siglec-9 could prevent down-regulation of the immune responsiveness of neutrophil and provide an antibacterial benefit against Group B Streptococcus infection by competitively inhibiting binding of capsular polysaccharide to Siglec-9 on neutrophil surfaces. Tomioka et al. reported that sSiglec-9 exerted an antitumor effect against Mucin1-expressing tumors by avoiding Mucin1 binding to immune cell Siglec-9 resulting in negative immunomodulation and/or by inactivating tumor-associated Mucin1 signaling. Therefore, it was a reasonable assumption that sSiglec-9 might block the interaction of Siglec-9 with its ligands to disturb Siglec-9 function in COPD. This hypothesis was applied to understand why Siglec-9 and sSiglec-9 are increased in the excessive and uncontrolled neutrophil inflammatory airway disease. More specifically, Siglec-9 was of compensatory elevation in COPD and increased levels of sSiglec-9 might prevent Siglec-9 from activation via competitive inhibition of ligands binding to Siglec-9.

CS is the main risk factor for developing COPD which is accelerated through exacerbations caused by infection. Consistent with previous studies showing that LPS increases Siglec-9 or Siglec-E expression, we found

Figure 4. Effect of cytokines on Siglec-9 and sSiglec-9 expression. Neutrophils were isolated from peripheral blood of controls and incubated for 12 h in the absence or presence of recombinant cytokines. Following culture, neutrophil Siglec-9 expression was quantified by flow cytometry analysis, and sSiglec-9 levels in culture supernatant was determined by ELISA. (a,b) Siglec-9 expression was up-regulated after incubation with recombinant TNF-α and IL-8. (c,d) Levels of sSiglec-9 in culture supernatant were increased after stimulation with recombinant cytokines. Data are displayed as means ± SEM; n = 15. P values were calculated using paired t tests; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5. Dexamethasone augmented neutrophil Siglec-9 expression but not sSiglec-9 levels in culture supernatant. Neutrophils were isolated from peripheral blood of controls and incubated for 12 h in the absence or presence of dexamethasone. Following culture, neutrophil Siglec-9 expression was quantified by flow cytometry analysis, and sSiglec-9 levels in culture supernatant was determined by ELISA. (a) $10^{-4}$ M DEX augmented Sigled-9 expression. (b) DEX had no effect on sSiglec-9 levels in culture supernatant. Data are displayed as means ± SEM, n = 15. P values were calculated using paired t tests; *p < 0.05.

Figure 6. Soluble Siglce-9 increased oxidative burst in neutrophil and enhanced neutrophil chemotaxis toward IL-8 independent of CXCR1 and CXCR1 expression. Neutrophils were isolated from peripheral blood of controls and were pretreated with sSiglec-9 or recombinant IL-8 for 2 h. (a) 100 ng/ml sSiglec-9 and 50 ng/ml sSiglec-9 IL-8 significantly boosted levels of oxidative burst in neutrophil by flow cytometric analysis. (b) $1 \times 10^6$ cells were added to the upper chamber and incubated in the absence or presence of IL-8 in lower compartments. Different concentrations of sSiglec-9 enhanced neutrophil migration toward IL-8. (c and d) Different concentrations of sSiglec-9 failed to affect the expression of CXCR1 and CXCR2 on neutrophil. Data are displayed as means ± SEM, n = 15. P values were calculated using paired t tests; *p < 0.05, **p < 0.01, ***p < 0.001.
that LPS induced Siglec-9 expression in peripheral blood neutrophil, it turned out to be truth for CSE. Besides, CSE and LPS could induce sSiglec-9 expression in the culture supernatant. Thus, CSE and LPS partially accounted for higher expression of Siglec-9 and sSiglec-9 in COPD.

Figure 7. No effect of sSiglec-9 on neutrophil apoptosis and inflammatory cytokine secretion. (a) High levels of CSE (2.5%) induced apoptosis of neutrophils isolated from peripheral blood of controls, whereas 10 ng/ml LPS reduced apoptosis. No effect of sSiglec-9 on neutrophil apoptosis were detected through the binding of annexin V-FITC and PI. Both 0.5% CSE and 10 ng/ml LPS increased neutrophils secretion of IL-6 (b), IL-8 (c) and TNF-α (d) but none were affected by sSiglec-9. Data are displayed as means ± SEM, n = 15. P values were calculated using paired t tests; *p < 0.05, **p < 0.01, ***p < 0.001.

Figure 8. Soluble Siglec-9 enhanced LPS-induced HBE secretion of IL-8. HBE was pretreated with sSiglec-9 for 1 h and then treated with CSE and LPS. CSE and LPS increased IL-8 (a) and IL-6 (b) secretion in HBE. (a) Both 10 ng/ml and 100 ng/ml sSiglec-9 enhanced IL-8 secretion induced by LPS. Data are displayed as means ± SEM, n = 5. P values were calculated using one-way ANOVA with Newman-Keuls post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001.
CSE and LPS resulted in up-regulated production of pro-inflammatory cytokines which were involved in the pathogenesis of COPD. We found that TNF-α and IL-8 increased both Siglec-9 and sSiglec-9 expression whereas IL-6 only augmented sSiglec-9 production. Therefore, TNF-α and IL-8 might attribute to CSE- and LPS-induced Siglec-9 expression. In addition, TNF-α, IL-6, and IL-8 might account for CSE- and LPS-induced sSiglec-9 production.

Leukocyte migration is critical to maintaining host defense but uncontrolled cellular infiltration into tissues can lead to chronic inflammation. One key feature of COPD is excessive neutrophilic airway inflammation, The accumulation of neutrophil can be due to increased neutrophil recruitment, delayed spontaneous apoptosis, or repression of the clearance of apoptotic neutrophil by tissue macrophages. IL-8 is elevated in the airways of COPD patients and was one of the chemotactic factors generated at the site of inflammation. It is a powerful mediator of neutrophil migration and activation. Our results found sSiglec-9 enhanced neutrophil migration toward IL-8 but had no influences on apoptosis. It was reasonable to postulate that high levels of sSiglec-9 partly contributed to excessive neutrophilic airway inflammation in COPD by elevating neutrophil recruitment. Siglec-9 and Siglec-E are important negative regulators of neutrophil and dendritic cells recruitment. Therefore, sSiglec-9 increased neutrophil chemotactic response probably through binding to Siglec-9 ligands to block Siglec-9 activation.

IL-8 activates neutrophil via CXCR1 and CXCR2; the latter appears to be the predominant receptor mediating its chemotactic response. Circulating neutrophil CXCR1 expression is significantly higher in COPD patients than in controls. We detected that neutrophil CXCR1 and CXCR2 expression were not changed after incubation with sSiglec-9 for 2 h; therefore, sSiglec-9 enhanced neutrophil chemotaxis toward IL-8 was independent of CXCR1 and CXCR2 expression. The precise mechanisms of neutrophil chemotactic response toward IL-8 requires further investigation.

Considerable evidence links COPD with increased oxidative stress. Circulating neutrophil from cigarette smokers and patients with exacerbations of COPD exhibit more oxidant burden, possibly due to the fact that cigarette smoke contains more than 1014 oxidants per puff and that infection and air pollutants have the potential to produce oxidative stress. Although engagement of Siglec-9 or Siglec-E suppressed oxidative stress, we observed that sSiglec-9 significantly boosted levels of oxidative burst in neutrophil in the present study. This observation may be due to sSiglec-9 competitive inhibiting ligands of siglec-9 binding to siglec-9.

Neutrophil apoptosis is associated with inflammatory diseases and appears to be regulated by neutrophil survival cytokines, such as granulocyte/macrophage colony-stimulating factor (GM-CSF). Several in vitro experiments have shown that Siglec-9 engagement with antibodies causes neutrophil death, especially in some cytokine-primed cells. GM-CSF has been considered to be a survival factor for neutrophil but GM-CSF was showed to promote death of neutrophil in association with Siglec-9 cross-linking when neutrophil was preincubated with GM-CSF and subsequently Siglec-9 stimulated. When GM-CSF was added at the same time or after the addition of an anti-Siglec-9 antibody, the cytokines had no effect. The mechanisms underlying the interplay of neutrophil survival cytokines and Siglec-9 are complex and not completely resolved. In our study, spontaneous neutrophil apoptosis was not altered by sSiglec-9 stimulation; high level CSE-induced and LPS-reduced neutrophil apoptosis were also not affected, possibly due to the interplay of neutrophil survival cytokines and Siglec-9.

Matsubara et al. observed only a combination of monocyte chemoattractant protein-1 and sSiglec-9, but not alone, repaired spinal cord injury by anti-inflammatory M2-like macrophage induction. However, Matsumoto et al. reported that sSiglec-9 alone alleviated the joint inflammation and destruction in a collagen-induced arthritis by suppression of M1 proinflammatory macrophage, which led to lower levels of TNF-a and IL-6. Contrary to their results, we found that Siglec-9 had no effect on neutrophil or smooth muscle cell (data not shown) secretion of inflammatory cytokines but enhanced LPS-induced HBE secretion of IL-8 which might subsequently recruit more neutrophil into the lungs. Thus, this result highlighted that sSiglec-9 might induce a positive feedback loop to aggregate airway inflammation in COPD by enhancing IL-8 production under infection. The impacts of sSiglec-9 on cytokine secretion appear to be cell type-specific or dependent on cytokines in the circumstance.

Corticosteroids, anti-inflammatory drugs, are therapeutic agents for relieving COPD symptoms. Siglec-5/14 expression is significantly higher in sputum cells from COPD patients receiving inhaled corticosteroids than those without them. DEX is a synthetic corticosteroid and has been widely used for the treatment of COPD. In the current study, we found that DEX augmented neutrophil Siglec-9 expression but not sSiglec-9 levels in culture supernatant. These results indicate that DEX might exert an anti-inflammatory effect on neutrophil by up-regulating Siglec-9 expression.

In conclusion, Siglec-9 was complementarily increased to serve as a negative feedback loop to limit neutrophil activation in COPD. Soluble Siglec-9 was higher in COPD patients and subsequently enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibition of ligands binding to Siglec-9. Furthermore, DEX might exert an anti-inflammatory role through up-regulating Siglec-9 expression.

**Methods**

**Subjects.** A total of 51 COPD patients and 23 healthy controls were included in our study. The clinical characteristics of them are described in Supplementary Table S1. The COPD patients were recruited from outpatient of the Tongji hospital between April 2014 and April 2016. COPD was diagnosed according to the criteria established by the NHLBI/WHO Global Initiative for COPD. Control subjects were selected from a pool of healthy men who visited the general health check-up center in the Tongji hospital. Subjects were excluded if they suffered from asthma, other obstructive lung diseases, tumors or a course of oral corticosteroids in the previous 4 weeks. 15 ml blood samples were collected from all participants.

Bronchoalveolar lavage fluid (BALF) was obtained from subjects who were required bronchoscopic evaluation of a solitary pulmonary nodule between September 2016 and June 2017 in Tongji hospital. A total of 10 COPD...
patients and 16 controls were included. The clinical characteristics of them are shown in Supplementary Table S2. Subjects with history of asthma, allergy, pneumonia, interstitial lung diseases and bronchiectasis were excluded.

Lung tissues specimens were collected during surgical resection of solitary pulmonary nodules as described previously48. This study was conducted in compliance with the institutional policy regarding the protection of patients’ private information and approved by the Ethical Committee of Tongji Hospital, Huazhong University of Science and Technology (IRB ID: 20140415). Written informed consent was obtained from all participants. Sample collection and all the experimental methods in our study were carried out in accordance with the approved guidelines.

**Isolation and culture of neutrophil.** Neutrophil was isolated from peripheral blood by Ficoll-Hypaque gradient centrifugation as described previously49. Briefly, peripheral blood was mixed with equal volume of hydroxyethyl starch 550 (TBDScience, Tianjin, China) and PBS, and allowed to sediment for 30 min at room temperature. The leukocyte containing supernatant was then carefully layered onto gradient reagent (TBDScience, Tianjin, China). After centrifugation at 800 g for 25 min, all the layers without polymorphonuclear (PMN) were removed. This method routinely yielded a purity >98% as determined by Wright-Giemsa staining. The viability of isolated cells was found to be greater than 96% with trypan blue (Sigma, St. Louis, USA) exclusion. After washing in phosphate-buffered saline solution, both cells were suspended at concentration of 5 × 106 cells/mL in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY) in 6-well plates (Nest, China).

**BALF collection and isolation of Bronchoalveolar Macrophage.** During fiberoptic bronchoscopy, BALF was collected prior to any other procedures according to international guidelines50. The bronchoscope was wedged in the subsegmental bronchus of the middle lobe not containing any nodule. The bronchus was lavaged with 50 ml aliquots of sterile saline solution at 37°C and then the fluid was aspirated. Two further 50 ml aliquots of saline solution were instilled and aspirated in the same way. Aliquots were transferred to 50 ml polypropylene tubes on ice.

BALF was strained through a 40um cell strainer (Millipore, Germany) and then centrifuged at 500 × g for 10 min at 4°C. The cell pellet was resuspended in 2 ml RPMI 1640 and total cell viability was determined by trypan blue exclusion. Slides were prepared by cytocentrifugation at 500 × g for 5 min. slide were stained with a standard May-Grünwald Giemsa stain and a differential count was performed by examining 300 cells. Other slides were fixed by 4% formaldehyde for immunofluorescence.

Bronchoalveolar macrophage were allowed to adhere to sterile 6-well polystyrene culture plates (Costar, NY, USA) at 37°C for 2 h. Nonadherent cells were removed by washing the monolayers with PBS, yielding monolayers that contained at least 95% macrophages by morphologic criteria. 1 ml TRIzol was added for extracting total RNA.

**Cell stimulation.** To determine the siglec-9 expression on neutrophil surface, cells were stimulated with different concentration of CSE51, LPS (sigma-Aldrich, St. Louis, USA), TNF-α, IL-6 and IL-8 (Peprotech, Rocky Hill, USA) for indicated time. In order to determine the effect of Ssiglec-9 on neutrophil or bronchial epithelial cells (HBE) (ATCC, VA, USA) cytokines secretion, cells were pretreated with recombinant siglec-9 (sSiglec-9) (R&D Systems, Minneapolis, USA) for 1 h, and then treated with CSE or LPS for indicated time. Supernatants were stored at −80°C for ELISA analysis, and cells were collected for detection.

**Flow cytometry.** After treatment, cells were washed and resuspended in 300μl Cell Staining Buffer (Biologend, San Diego, USA). Cells were incubated with the appropriate primary antibodies for 30 minutes in the dark. Primary antibodies are as following: Human Siglec-9 Fluorescein (FITC)-conjugated antibody and IgG2A isotype control-FITC were obtained from R&D Systems (Minneapolis, USA); Human CXCR1 FITC-conjugated antibody, IgG2B isotype control-FITC, Human CXCR2 phycoerythrin (PE)-conjugated antibody as well as IgG1 isotype control-PE were obtained from Biologend (San Diego, USA). Samples were washed twice in ice-cold PBS and resuspended in 300μl Cell Staining Buffer (Biologend, San Diego, USA), and then assessed by flow cytometry using a Becton Dickinson LSR flow cytometer48.

**Intracellular ROS detection.** Intracellular ROS level was detected using Reactive Oxygen Species Assay Kit (Beyotime, Jiangsu, China). Neutrophil was pretreated with sSiglec-9 or recombinant IL-8 for 2 h. After treatment, cells were washed and incubated in RPMI 1640 medium with 10 μM dichlorofluorescein diacetate (DCFH-DA) for 20 min. Subsequently, the cells were washed 3 times with the RPMI 1640 medium without serum. Finally, the cells were resuspended with 300 μl PBS, and the mean fluorescent signal intensity (MFI) of dichlorofluorescein (DCF) was determining by flow cytometry.

**Assessment of apoptosis.** An annexinV–fluorescein isothiocyanate (FITC) apoptosis detection kit (KeyGEN; Nanjing, China) was used for detection of neutrophil apoptosis49.

**Immunofluorescence and H&E staining.** After rehydration in a graded alcohol series, slides of BALF were washed in TBS and heated at 100°C for 10 min in sodium citrate buffer for epitope retrieval. Slides were incubated with blocking reagent (Dako Japan Ltd., Kyoto, Japan) for 1 h at room temperature, and then were incubated overnight with anti-CD68 antibody (Abcam, Cambridge, UK) plus anti-Siglec-9 antibody (R&D Systems, Minneapolis, USA) or matched isotype controls (Becton Dickinson) at 4°C. After washing, slides were incubated with Alexa Fluor 594-goat anti-mouse and Alexa Fluor 488-donkey anti-goat secondary antibody (Invitrogen, California, USA) for 60 min at room temperature. Nuclei were counterstained with DAPI. Subsequently, H&E staining were carried out in the slides which were double immunostaining for Siglec-9 and CD68.
**Immunohistochemistry.** The lung sections were stained with anti-Siglec-9 antibody (R&D Systems, Minneapolis, USA) using a modified method as previously described. A Nikon Spot image acquisition and processing system was used for image assessment.

**RNA isolation and quantitative real-time PCR.** Total RNA was extracted and real-time PCR was performed as described previously. Primers were as follows: \(\beta\)-actin F-5′-AGAAATCTGGCCAACCACCT-3′, \(\beta\)-actin R-5′-GATAGCAGACGCT-GGATAGCA-3′, Siglec-9 F-5′-CCACATACGAAGATTGCAAGC-3′, Siglec-9 R-5′-ACAGAGAGCCGTGATTTAT-3′.

**Neutrophil chemotaxis assays.** The activity of neutrophil migration was estimated through a polycarbonate filter with 3-μm pore size in 24-well transwell chambers (Costar, NY, USA). Neutrophil was incubated with sSiglec-9 for 2 hours in RPMI 1640 medium supplemented with 2% heat-inactivated FCS. Lower compartments were filled with 500 μl RPMI 1640 medium with or without 50 μg/ml IL-8 (Peprotech, Rocky Hill, USA). Then, 200 μl neutrophil suspension (1 × 10^6/ml) was added to upper chamber and incubated for 1 hour. Cells on the lower surface of the filters and in the lower chamber were harvested in 300 μl PBS and counted by flow cytometry acquiring events for a fixed time period of 60 seconds.

**Enzyme linked immunosorbent assay (ELISA).** Concentrations of IL-6, IL-8 and TNF-α in cell-free culture supernatants or sSiglec-9 in plasma were measured using DuoSet ELISA kits (R&D Systems, Minneapolis, USA) as described previously. The limits of detection for the IL-6, IL-8, TNF-α and sSiglec-9 ELISA kits were 9.38, 31.3, 15.6 and 62.5 pg/mL, respectively.

**Statistical analyses.** Data were presented as means ± SEM. Statistical analyses were performed using Prism 5 software (GraphPad Software Inc., San Diego, USA). Normally distributed data were analyzed using Student’s t test for two groups and one-way ANOVA with Newman-Keuls post hoc test for multiple comparisons. Data which did not meet normally distribution were evaluated by Mann-Whitney U-test. The chi-square test was used to compare proportions in two groups. The number (n) of independent experiments were indicated in each case. All data were analyzed using two-tailed tests, P < 0.05 was considered to indicate a statistically significant difference.

**References**

1. Fang, X., Wang, X. & Bai, C. COPD in China: the burden and importance of proper management. Chest 139, 920–929 (2011).
2. Vestbo, J. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine 187, 347–365 (2013).
3. Meijer, M., Rijkers, G. T. & van Overveld, F. J. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert review of clinical immunology 9, 1055–1068 (2013).
4. Barnes, P. J. Immunology of asthma and chronic obstructive pulmonary disease. Nature reviews. Immunology 8, 183–192 (2008).
5. Oudijk, E. J., Lammers, J. W. & Koenderman, L. Systemic inflammation in chronic obstructive pulmonary disease. The European respiratory journal. Supplement 46, 5s–13s (2003).
6. Ekberg-Jansson, A. et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(1CO) and to emphasphysmatic changes on high resolution CT. Respiratory medicine 95, 363–373 (2001).
7. Rahman, I. & Adcock, I. M. Oxidative stress and redox regulation of lung inflammation in COPD. The European respiratory journal 28, 219–242 (2006).
8. Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nature reviews. Immunology 7, 255–266 (2007).
9. Crocker, P. R. Siglecs in innate immunity. Current opinion in pharmacology 3, 431–437 (2005).
10. von Guntzen, S. et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 106, 1423–1431 (2005).
11. Avril, T., Floyd, H., Lopez, F., Vivier, E. & Crocker, P. R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. Journal of immunology 173, 6841–6849 (2004).
12. McMillan, S. J., Sharma, R. S., Richards, H. E., Hegde, V. & Crocker, P. R. Siglec-E promotes beta2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung. The Journal of biological chemistry 289, 20370–20376 (2014).
13. McMillan, S. J. et al. Siglec-9 is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signaling. Blood 121, 2084–2094 (2013).
14. Schwarz, F. et al. Siglec receptors impact mammalian lifespan by modulating oxidative stress. eLife 4 (2015).
15. Angata, T. et al. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cellular and molecular life sciences: CMLS 70, 3199–3210 (2013).
16. Wielgat, P. et al. Inhaled corticosteroids increase siglec-5/14 expression in sputum cells of COPD patients. Advances in experimental medicine and biology 839, 1–5 (2015).
17. Ishii, T. et al. Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency. Respiratory medicine 113, 1559–1566 (2019).
18. Carlin, A. F. et al. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113, 3333–3336 (2009).
19. Belisle, J. A. et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Molecular cancer 9, 118 (2010).
20. Saito, M. et al. A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice. Microbial pathogenesis 99, 106–110 (2016).
21. Tomioka, Y. et al. A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice. Biochemical and Biophysical Research Communications 450, 532–537 (2014).
22. Hele, D. J. & Belvisi, M. G. Novel therapies for the treatment of inflammatory airway disease. Expert opinion on investigational drugs 12, 3–18 (2003).
23. Wuyts, A. et al. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. European journal of biochemistry 255, 67–73 (1998).
24. Stanescu, D. et al. Airways obstruction, chronic expectation, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51, 267–271 (1996).
25. Lapperre, T. S. et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 131, 53–59 (2007).
26. Cosio, M. G., Saetta, M. & Agusti, A. Immunologic aspects of chronic obstructive pulmonary disease. The New England journal of medicine 360, 2445–2455 (2009).
27. Donaldson, G. C., Seemungal, T. A., Bhowmik, A. & Wedzicha, J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847–852 (2002).
28. Ando, M., Tu, W., Nishijima, K.-i. & Iijima, S. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochemical and Biophysical Research Communications 369, 878–883 (2008).
29. Boyd, C. R. et al. Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. Journal of immunology 183, 7703–7709 (2009).
30. Caramori, G., Adecock, I. M., Di Stefano, A. & Chung, K. F. Cytokine inhibition in the treatment of COPD. International journal of chronic obstructive pulmonary disease 9, 397–412 (2014).
31. Geng, J. G. Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies. Cell research 11, 85–88 (2001).
32. Sapey, E. et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 183, 1176–1186 (2011).
33. Pletz, M. W., Ioanas, M., de Roux, A., Burkhardt, O. & Lode, H. Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. The European respiratory journal 23, 532–537 (2004).
34. Minematsu, N., Blumenthal-Perry, A. & Shapiro, S. D. Cigarette smoke inhibits engulfment of apoptotic cells by macrophages through inhibition of actin rearrangement. American journal of respiratory cell and molecular biology 44, 474–482 (2011).
35. Yamamoto, C. et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 112, 505–510 (1997).
36. Schulz, C. et al. Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration; international review of thoracic diseases 70, 254–261 (2003).
37. Yamagata, T. et al. Overexpression of CD-11b and CXCR1 on circulating neutrophils: its possible role in COPD. Chest 132, 890–899 (2007).
38. McCusker, K. Mechanisms of respiratory tissue injury from cigarette smoking. The American journal of medicine 93, 188–215 (1992).
39. Rahman, I., Morrison, D., Donaldson, K. & MacNee, W. Systemic oxidative stress in asthma, COPD, and smokers. American journal of respiratory and critical care medicine 154, 1055–1060 (1996).
40. Pryor, W. A. & Stone, K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrite, and peroxynitrite. Ann N Y Acad Sci 686, 12–27 (1993).
41. Repine, J. E., Bast, A. & Lankhorst, I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. American journal of respiratory and critical care medicine 156, 341–357 (1997).
42. Secundino, I. et al. Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation. Journal of molecular medicine (2015).
43. Colotta, F., Re, F., Polentarutti, N., Sozzani, S. & Mantovani, A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80, 2012–2020 (1992).
44. von Gunten, S. et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108, 4255–4259 (2006).
45. Matsubara, K. et al. Secreted ectodomain of sialic acid-binding lg-like lectin-9 and monocye chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity. The Journal of neuroscience: the official journal of the Society for Neuroscience 35, 2452–2464 (2015).
46. Yamagata, T. et al. Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages. Arthritis research & therapy 18, 133 (2016).
47. Rabe, K. F. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine 176, 532–555 (2007).
48. Xia, J. et al. Increased IL-33 expression in chronic obstructive pulmonary disease. American journal of physiology. Lung cellular and molecular physiology 308, L619–627 (2015).
49. Wang, M. et al. Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma. Respiratory research 17, 153 (2016).
50. Meyer, K. C. et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American journal of respiratory and critical care medicine 185, 1004–1014 (2012).
51. Xu, Y. et al. Cigarette smoke (CS) and nicotine delay neutrophil spontaneous death via suppressing production of diphosphoinositol pentakisphosphate. Proceedings of the National Academy of Sciences of the United States of America 110, 7726–7731 (2013).
52. Giaid, A. et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341, 1550–1554 (1993).
53. Rios-Santos, F. et al. Down-regulation of CXCR2 on neutrophils in severe sepsis is mediated by inducible nitric oxide synthase-derived nitric oxide. American journal of respiratory and critical care medicine 175, 490–497 (2007).
54. Scandellia, E. et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354–1361 (2002).

Acknowledgements
The authors thank the patients who volunteered for this study; Jie Xia and Xiaocheng Li for referring subjects with COPD for the study. This study was supported by the National Natural Science Foundation of China (No. 81570033, 81570047, 81470227, 81370145, 81370156), National Key Basic Research and Development Program (973 Program, No. 2015CB553403), Chinese Medical Association Research Project (No. 2013BAI09B00) and Changjiang Scholars and Innovative Research Team in University (No. IRT_14R20).

Author Contributions
J.X. is the guarantor of the manuscript. Z.Z. and J.X. designed and conducted the study, statistical analyses, conceived of the manuscript and had responsibility for writing. M.L., M.W., X.W. and Q.L. performed sample collection and sample analyses. Q.N. and Y.X. assisted with statistical analyses and writing of the manuscript. All authors reviewed and approved the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09120-5

Competing Interests: The authors declare that they have no competing interests.
